SCHEMBL4848802

SCHEMBL4848802

CN1C(=O)OC(C)(C)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.51
LMNA P02545 5/20 0.48
MAPT P10636 7/20 0.44
HTT P42858 4/20 0.44
KDM4E B2RXH2 2/20 0.44
HCRTR1 O43613 1/20 0.44
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
USP2 O75604 3/20 0.40
ELANE P08246 1/20 0.40
CTSG P08311 1/20 0.40
PRTN3 P24158 1/20 0.40
ALDH1A1 P00352 4/20 0.40
TP53 P04637 2/20 0.40
NPC1 O15118 2/20 0.40
AKR1B1 P15121 1/20 0.40
RAD52 P43351 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20616487 0.78 ELANE (0.45) PGRLMNAMAPTKDM4ESMN1; SMN2
SCHEMBL16427152 0.76 PGR (0.60) PGRLMNAMAPTSMN1; SMN2KMT2A
SCHEMBL631694 0.74 ELANE (0.41) PGRLMNAMAPTKDM4ESMN1; SMN2
SCHEMBL13314895 0.74 SIGMAR1 (0.46) ALDH1A1TP53
SCHEMBL11098168 0.73 ELANE (0.40) PGRLMNAMAPTKDM4EHCRTR1
SCHEMBL7654525 0.73 SIGMAR1 (0.40) LMNAMAPTKDM4EHCRTR1SMN1; SMN2
SCHEMBL4848255 0.73 PGR (0.53) PGRLMNASMN1; SMN2MEN1KMT2A
SCHEMBL4851150 0.72 PGR (0.70) PGR
SCHEMBL628924 0.72 ELANE (0.40) PGRLMNAMAPTKDM4ESMN1; SMN2
SCHEMBL4172878 0.72 PGR (0.73) PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354915-B2 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators WYETH (US) 2008-04-08 US disclosed
US-20070225281-A1 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators WYETH (US) 2007-09-27 US disclosed
US-7247625-B2 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators WYETH (US) 2007-07-24 US disclosed
US-20050085470-A1 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators WYETH 2005-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085470-A1 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators PGR, FSHR, GPR6 PGR 1/4885LMNA 4353/4885MAPT 4773/4885
US-20070225281-A1 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators PGR, FSHR, GPR6 PGR 1/4885LMNA 4353/4885MAPT 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.